- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01381809
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
14 maart 2016 bijgewerkt door: Janssen-Cilag International NV
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes
The purpose of this study is to demonstrate that epoetin alfa works better than placebo in improving anemia in patients with lower-risk myelodysplastic syndromes (MDS).
The safety of epoetin alfa will also be evaluated.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a randomized (the treatment you receive will be assigned by chance), double-blind (neither physician nor patient knows the name of the assigned drug), placebo-controlled (comparison with patients that receive treatment without active ingredient), multicenter study of epoetin alfa in anemic patients who are diagnosed with myelodysplastic syndromes (MDS) according to protocol-specified criteria.
This study includes a 3-week prerandomization phase, a 24-week treatment phase and a 24-week treatment extension phase.
All patients enrolled in the study will complete an end-of-study visit 4 weeks after the last dose of study drug (Week 28 or Week 52), or 4 weeks after early withdrawal (unless the reason for early withdrawal is withdrawal of consent).
Between 125 and 159 patients will be enrolled in the treatment phase of the study.
During the screening phase, which will take place within 2 weeks before starting study drug, the study doctor will do tests to see if the patient is suitable for this study.
Patients meeting entry criteria for the study will then be randomly assigned to one of the 2 treatment groups.
This means that each patient who is allowed to join the study is put into a group by chance, like flipping a coin.
Group 1 patients will receive epoetin alfa 450 or increased up to 1050 International Units (IU) per kg body weight administered by subcutaneous injection (injection beneath the skin) using pre-filled syringes.
Injections will be done once every week at a weight-based dose regimen (the total weekly dose received will depend on your weight) with a possible total maximum dose of 40,000 IU once every week for the first 8 weeks of the treatment phase and 80,000 IU once every week at any other time during the study.
Group 2 patients will receive a matching volume of placebo administered once every week by subcutaneous injection.
The chance that the patient will get epoetin alfa is 2 to 1. Doses of study drug will be withheld, decreased, or increased on the basis of erythroid response, weekly hemoglobin concentrations monitored in patients and predefined dose adjustment guidelines.
Patients will see the study doctor every 4 weeks for a period of 24 weeks.
At each visit the patient will undergo a full hematologic evaluation, serum chemistry evaluation, measurement of blood pressure and pulse rate, recording of blood product transfusions and transfusion complications, adverse events, concomitant therapies and an evaluation for disease progression.
The patient's Erythroid response will be assessed at Week 8 and every 4 weeks thereafter, until Week 24.
Blinded study treatment will be administered to all patients at Week 24.
However, at the end of the treatment phase (after the Week 24 response assessment), only responders will enter the double-blind treatment extension phase to measure the duration of response.
Patients will continue to receive the same treatment, in the same blinded fashion, and at the same dose as received at Week 24, and will return to the study center every 4 weeks, until Week 48, for assessment of the Erythroid response and the evaluations as described above.
For all non-responders at Week 24 the treatment code will be broken after Week 28 assessments.
For responders at Week 48, the treatment code will be broken after the Week 48 visit, following completion of the response assessment.
The treatment code will not be broken for subjects who discontinue study treatment before Week 24, irrespective of whether they are responders or nonresponders.
For these subjects, the blind will not be broken until all subjects have completed the study and the database is final.
Once the patient stops receiving doses of study drug, he/she will be asked to see the study doctor for the safety follow-up visit, which is scheduled 4 weeks after the last dose of study drug.
Safety will be monitored throughout the study at predetermined intervals and as clinically indicated by physical examination, laboratory tests and evaluation of adverse events.
An Independent Data Monitoring Committee (IDMC) will periodically review study data and for the assessment of disease progression.
The total duration of study participation will be for about 30 or 54 weeks.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
130
Fase
- Fase 3
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
-
Plovdiv, Bulgarije
-
Sofia, Bulgarije
-
Varna, Bulgarije
-
-
-
-
-
Berlin, Duitsland
-
Dresden, Duitsland
-
Duisburg, Duitsland
-
Düsseldorf, Duitsland
-
Dÿsseldorf, Duitsland
-
München, Duitsland
-
Oldenburg, Duitsland
-
Würzburg, Duitsland
-
-
-
-
-
Amiens, Frankrijk
-
Angers Cedex 9, Frankrijk
-
Bobigny, Frankrijk
-
Colmar, Frankrijk
-
Paris Cedex 10, Frankrijk
-
Pessac Cedex, Frankrijk
-
Pierre Benite Cedex, Frankrijk
-
Saint Priest En Jarez, Frankrijk
-
Tours Cedex 9, Frankrijk
-
Vandoeuvre Les Nancy, Frankrijk
-
-
-
-
-
Athens, Griekenland
-
Goudi-Athens, Griekenland
-
Larisa, Griekenland
-
Patra, Griekenland
-
Thessalonikis, Griekenland
-
-
-
-
-
Ekaterinburg, Russische Federatie
-
St. Petersburg, Russische Federatie
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Diagnosis of MDS according to World Health Organization or French-American-British pathologic classification (confirmed via bone marrow aspirate/biopsy) within 12 weeks prior to screening
- Documentation of an International Prognostic Scoring System score indicating Low- or Intermediate-1-risk disease within 12 weeks prior to screening
- Hemoglobin concentration at screening and baseline (before the first dose of study drug) of 10.0 g/dL or less
- Screening serum erythropoietin concentration of less than 500 mU/mL
- Red Blood Cell transfusion requirement of less than or equal to 4 red blood cell units over the last 8 weeks before randomization
Exclusion Criteria:
- Anemia attributed to factors other than MDS (including hemolysis, chronic renal failure, hepatitis, gastrointestinal bleeding)
- Secondary MDS (ie, MDS arising after chemotherapy, immunotherapy or radiation therapy/exposure)
- History of malignancy, except in situ skin basal cell carcinoma or carcinoma in situ of the cervix or breast curatively treated
- Prior therapy with any erythropoiesis-stimulating agent (ESA) (including innovative ESAs and biosimilar ESAs for approved indications or for investigational use) in the last 8 weeks before randomization
- Prior use of approved or experimental agents for the treatment of MDS
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Epoetin alfa
Group 1: Epoetin alfa type = range unit= IU/Kg number= 337.5 to 1050 IU/Kg form= solution for injection route= subcutaneous use weekly injections (max 40 000 IU per week for first 8 weeks of treatment max 80 000 IU per week later) using pre-filled 1mL 40 000 IU syringes for 24 to 48 weeks
|
type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
|
Placebo-vergelijker: No treatment
Group 2: Placebo form= solution for injection route= subcutaneous use weekly injections for 24 to 48 weeks
|
form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Erythroid response
Tijdsspanne: at week 24
|
at week 24
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Maintenance of Erythroid response
Tijdsspanne: every 4 weeks from week 24 to week 48
|
every 4 weeks from week 24 to week 48
|
Duration of response
Tijdsspanne: every 4 weeks after week 24
|
every 4 weeks after week 24
|
Time to first Red Blood Cell transfusion
Tijdsspanne: from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)
|
from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)
|
Transfusion-free intervals
Tijdsspanne: from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)
|
from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)
|
Number of Red Blood Cell units transfused
Tijdsspanne: from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)
|
from baseline to study end (week 28 for non responders, week 54 for responders or 4 weeks after early withdrawal)
|
Quality of life as measured by Functional Assessment of Cancer Therapy-Anemia/Fatigue (FACT-An) questionnaire
Tijdsspanne: at baseline, week 24 and week 48
|
at baseline, week 24 and week 48
|
Quality of life as measured by EuroQol 5-dimension (EQ-5D) questionnaire
Tijdsspanne: at baseline, week 24 and week 48
|
at baseline, week 24 and week 48
|
Drug consumption
Tijdsspanne: every 4 weeks from baseline to week 48
|
every 4 weeks from baseline to week 48
|
Duration of hospitalization
Tijdsspanne: every 4 weeks from baseline to week 48
|
every 4 weeks from baseline to week 48
|
Number and duration of medical care encounters
Tijdsspanne: every 4 weeks from baseline to week 48
|
every 4 weeks from baseline to week 48
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start
1 oktober 2011
Primaire voltooiing (Werkelijk)
1 januari 2015
Studie voltooiing (Werkelijk)
1 januari 2016
Studieregistratiedata
Eerst ingediend
23 juni 2011
Eerst ingediend dat voldeed aan de QC-criteria
23 juni 2011
Eerst geplaatst (Schatting)
27 juni 2011
Updates van studierecords
Laatste update geplaatst (Schatting)
16 maart 2016
Laatste update ingediend die voldeed aan QC-criteria
14 maart 2016
Laatst geverifieerd
1 maart 2016
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CR018367
- EPOANE3021 (Andere identificatie: Janssen-Cilag International NV)
- 2010-022884-36 (EudraCT-nummer)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Myelodysplastische syndromen
-
The Champ FoundationChildren's Hospital of Philadelphia; The Cleveland ClinicWervingPearson-syndroom | Single Large Scale Mitochondrial DNA Deletion Syndromes (SLSMDS)Verenigde Staten
Klinische onderzoeken op Group 1: Epoetin alfa
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RSVoltooidVergelijking van de werkzaamheid van twee formuleringen van epoëtine bij patiënten die hemodialyse ondergaan
-
Ortho Biotech Products, L.P.Voltooid
-
Johnson & Johnson Pharmaceutical Research & Development...VoltooidBloedarmoedeVerenigde Staten, Puerto Rico
-
Bio Sidus SAVoltooid
-
Penang Hospital, MalaysiaOnbekendEindstadium nierfalen | Bloedarmoede
-
Bio Sidus SAOnbekendBloedarmoede van chronische nierziekteArgentinië, Paraguay
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech, Inc.Voltooid
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.VoltooidNier Ziekten | Bloedarmoede
-
Johnson & Johnson Pharmaceutical Research & Development...VoltooidBloedtransfusie | Orthopedische operatie | Orthopedische procedures | Mammaplastie | Cardiovasculaire chirurgische ingrepen | Bloedtransfusie, autoloog